Glenmede Trust’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Glenmede Trust’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-700	Closed	-$17K	–	1514
2018 Q2	$17K	Hold	700	–	–	﹤0.01%	1757
2018 Q1	$16K	Hold	700	–	–	﹤0.01%	2039
2017 Q4	$16K	Hold	700	–	–	﹤0.01%	2039
2017 Q3	$18K	Hold	700	–	–	﹤0.01%	2004
2017 Q2	$17K	Hold	700	–	–	﹤0.01%	1969
2017 Q1	$17K	Hold	700	–	–	﹤0.01%	1969
2016 Q4	$14K	Hold	700	–	–	﹤0.01%	2007
2016 Q3	$18K	Hold	700	–	–	﹤0.01%	1960
2016 Q2	$15K	Hold	700	–	–	﹤0.01%	1983
2016 Q1	$15K	Buy	+700	New	+$14.9K	﹤0.01%	1900

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

CIA

Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return

Glenmede Trust's CNCR Position: Q3 2018 in Review

Glenmede Trust sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q3 2018, closing a stake of 700 shares — an estimated $17K sold.

Glenmede Trust first reported a position in CNCR in Q1 2016 and held it in 10 quarters. The position peaked at $18K in Q3 2017. 23 funds tracked by Wall St. Rank hold CNCR as of Q3 2018.

Glenmede Trust reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q3 2018 after selling out during the quarter.
Glenmede Trust sold 700 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q3 2018, an estimated $17K.
Glenmede Trust first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q1 2016 and held it in 10 quarters.
Glenmede Trust's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $18K in Q3 2017.
23 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q3 2018.

Based on Glenmede Trust's 13F filing for Q3 2018, filed 15 Nov 2018.